Cardinal Health (CAH) Q2 Earnings Strengthen Bullish Narrative On 26.7% TTM EPS Growth

Simply Wall St.

02/08

Cardinal Health (CAH) just posted its Q2 2026 numbers, with revenue of about US$65.6b, basic EPS of US$1.98 and net income excluding extra items of US$467m setting the tone for the latest update. Over...

网页链接

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2609521602"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2609521602\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2609521602?lang=zh_CN&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/company-cover/172207-main-header/1585186855368","is_english":true,"pubTime":"2026-02-08 03:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2609521602","market":"nz","top_or_hot":-1,"title":"Cardinal Health (CAH) Q2 Earnings Strengthen Bullish Narrative On 26.7% TTM EPS Growth","media":"Simply Wall St.","content":"<div>\n<p>Cardinal Health (CAH) just posted its Q2 2026 numbers, with revenue of about US$65.6b, basic EPS of US$1.98 and net income excluding extra items of US$467m setting the tone for the latest update. Over...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-cah/cardinal-health/news/cardinal-health-cah-q2-earnings-strengthen-bullish-narrative\">网页链接</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cardinal Health (CAH) Q2 Earnings Strengthen Bullish Narrative On 26.7% TTM EPS Growth</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCardinal Health (CAH) Q2 Earnings Strengthen Bullish Narrative On 26.7% TTM EPS Growth\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-08 03:08 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nyse-cah/cardinal-health/news/cardinal-health-cah-q2-earnings-strengthen-bullish-narrative><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Cardinal Health (CAH) just posted its Q2 2026 numbers, with revenue of about US$65.6b, basic EPS of US$1.98 and net income excluding extra items of US$467m setting the tone for the latest update. Over...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-cah/cardinal-health/news/cardinal-health-cah-q2-earnings-strengthen-bullish-narrative\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4099","symbol_name":"汽车制造商","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-cah/cardinal-health/news/cardinal-health-cah-q2-earnings-strengthen-bullish-narrative","article_id":"2609521602","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/company-cover/172207-main-header/1585186855368"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-cah/cardinal-health/news/cardinal-health-cah-q2-earnings-strengthen-bullish-narrative","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2609521602","pubTimestamp":1770491318,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Cardinal Health (CAH) just posted its Q2 2026 numbers, with revenue of about US$65.6b, basic EPS of US$1.98 and net income excluding extra items of US$467m setting the tone for the latest update. Over the last few quarters the company has seen revenue move from US$55.3b in Q2 2025 to US$60.2b in Q4 2025, US$64.0b in Q1 2026 and now US$65.6b in Q2 2026. Basic EPS stepped through US$1.65, US$1.00, US$1.89 and US$1.98 over the same periods, which feeds into trailing twelve month EPS of US$6.97...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"BK4099":"汽车制造商","LU0310799852.SGD":"FTIF - Templeton Global Equity Income A MDIS SGD","LU0006061336.USD":"Blackrock US Small and MidCap Opportunities A2 USD","LU1267930813.SGD":"FRANKLIN TEMPLETON SHARIAH GLOBAL EQUITY \"AS\" (SGD) ACC","LU1267930490.SGD":"TEMPLETON GLOBAL EQUITY INCOME \"AS\" (SGD) INC A","BK4585":"ETF&股票定投概念","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","LU0211328371.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (MDIS) (USD)   INC","BK4175":"保健护理产品经销商","LU1267930227.SGD":"TEMPLETON GLOBAL BALANCED \"AS\" (SGD) ACC A","LU0162691827.USD":"BGF US BASIC VALUE \"A4\" INC","CAH":"卡地纳健康","LU1880398471.USD":"AMUNDI FUNDS GLOBAL EQUITY \"A2\" (USD) ACC","LU1880398554.USD":"AMUNDI FUNDS GLOBAL EQUITY \"A2\" (USD) INC","LU0072461881.USD":"BGF US BASIC VALUE \"A2\" ACC","LU0128525689.USD":"TEMPLETON GLOBAL BALANCED \"A\"(USD) ACC","BK4588":"碎股","BK4523":"印度概念","LU0792757196.USD":"TEMPLETON SHARIAH GLOBAL EQUITY FUND \"A\" (USD) ACC","BK4112":"金融交易所和数据","LU0211327993.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (USD) ACC","LU0052756011.USD":"TEMPLETON GLOBAL BALANCED \"A\" (USD) INC","LU0310800965.SGD":"FTIF - Templeton Global Balanced A Acc SGD","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","LU0889566641.SGD":"FTSF - Templeton Shariah Global Equity A Acc SGD"},"translate_title":"康德乐(CAH)第二季度收益强化了TTM每股收益增长26.7%的看涨叙事","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CAH":1.98},"content_text":"Cardinal Health (CAH) just posted its Q2 2026 numbers, with revenue of about US$65.6b, basic EPS of US$1.98 and net income excluding extra items of US$467m setting the tone for the latest update. Over the last few quarters the company has seen revenue move from US$55.3b in Q2 2025 to US$60.2b in Q4 2025, US$64.0b in Q1 2026 and now US$65.6b in Q2 2026. Basic EPS stepped through US$1.65, US$1.00, US$1.89 and US$1.98 over the same periods, which feeds into trailing twelve month EPS of US$6.97 on revenue of US$244.7b. With net profit margins still thin but edging higher year over year, this set of results keeps the focus firmly on how efficiently the company is converting its scale into earnings. See our full analysis for Cardinal Health. With the latest figures on the table, the next step is to see how these results line up against the most common narratives around Cardinal Health and where the numbers start to challenge the story. Curious how numbers become stories that shape markets? Explore Community Narratives NYSE:CAH Revenue & Expenses Breakdown as at Feb 2026 AdvertisementTTM earnings growth outpaces revenue  Over the last twelve months, Cardinal Health generated US$244.7b in revenue and US$1,662m in net income excluding extra items, with Basic EPS at US$6.97 on a trailing basis. What stands out for a bullish view is that earnings grew 26.7% over the past year while trailing revenue moved from US$222.3b to US$244.7b. This strongly supports the idea that profit growth has been running ahead of top line expansion even as net margin sits at 0.7%.  Supporters who point to a 25.2% 5 year earnings growth rate can tie that to the latest twelve month net income of US$1,662m, which is higher than the US$1,312m to US$1,595m range shown in the earlier trailing periods. At the same time, the modest move in net margin from 0.6% to 0.7% shows that most of the bullish story still comes from steady profit growth on a very large revenue base rather than from high margins.   Strong profit growth on a thin margin base is exactly the kind of setup bulls like to unpack further in a full thesis, especially when they want to see how durable that pattern looks across different scenarios. 📊 Read the full Cardinal Health Consensus Narrative. P/E premium versus peers at 32x  The shares trade on a P/E of about 32x, compared with an average of 28.1x for peers and 23.2x for the wider US Healthcare industry, while the current price of US$226.32 also sits below an analyst price target of US$243.07. Critics who focus on valuation argue that a 32x P/E sets a high bar, and the figures here give them some support because forecast earnings growth of roughly 11% per year and revenue growth of about 8.1% per year are both below the 15.6% earnings growth cited for the broader US market.  The gap between the current share price of US$226.32 and the analyst price target of US$243.07 is relatively small compared with the P/E premium to sector and peer groups. Bears can point to this when they question how much upside is being priced in. On the other hand, the same valuation critics have to reconcile their case with the 26.7% earnings growth over the past year, which shows that recent profit expansion has been stronger than the forward growth rates now being discussed.   DCF fair value and debt risk in focus  The stock is described as trading around 53.5% below a DCF fair value of US$486.81, even as the company is flagged for carrying a high level of debt as a minor risk. What is interesting for a bullish angle is how a DCF fair value close to US$486.81, more than double the current US$226.32 share price, lines up with strong trailing earnings growth. The cautious note around leverage reminds investors that higher debt sits in the background of this model driven upside.  Supporters who lean on that DCF fair value can point to trailing EPS of US$6.97 and net income of US$1,662m as evidence that cash generation potential has scaled with revenue, which is a key input in many valuation frameworks. At the same time, the high debt flag means any bullish case that uses the DCF figure needs to stay grounded in how a 0.7% net margin and moderate forecast growth interact with interest costs and balance sheet strength.    Next Steps Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on Cardinal Health's growth and its valuation to see if today's price is a bargain. Add the company to your watchlist or portfolio now so you don't miss the next big move. See What Else Is Out There Thin 0.7% net margins, a 32x P/E premium to peers, and a high debt flag all point to meaningful risk around how earnings and leverage interact. If that mix of rich valuation and balance sheet pressure makes you uneasy, check out 86 resilient stocks with low risk scores to quickly zero in on companies with more resilience built in.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}